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Human malignant melanoma represents a difficult therapeu­
tic challenge to both medical scientists and practicing physi­
cians. However, the biologic uniqueness of the tumor may 
provide opportunities for exploitation in therapeutics. This 
study proposed to undertake a systemic approach to the 
chemotherapy of malignant melanoma based upon the 
uniqueness of pigment-cell metabolic pathway pertaining to 
conversion of tyrosine and dopa with subsequent formation 
of melanin by tyrosinase and its related enzymes. The sulphur 
homologue of tyrosine, cysteinylphenol (CP), its amine de­
rivative, cysteaminylphenol (CAP), and their N-acetyl and 
a-methyl derivatives have been synthesized and tested in in 
vivo and in vitro melanocytotoxicity and antimelanoma ef­
fects. These phenolic thioethers (PTEs) and phenolic 
thioether amine (amides) (PTEAs), which are substrates of 
H
uman malignant melanoma represents a difficult 
therapeutic challenge to the scientist and physician. 
Whereas great progress has been made in the early 
diagnosis of stage I melanoma (no palpable nodes) 
and survival has dramatically increased in the past 
decade or two, the mortality continues to increase at 3% per year [1]. 
Furthermore, we have no therapy for high-risk primary melanoma 
at stage I (lesions deeper than the level IV or 3.5 mm in tumor 
thickness) and no therapy at all for stage III melanoma. Cancer 
chemotherapy has failed, immunotherapy is virtually ineffective, 
and the overwhelming majority of melanomas are not radiorespon­
sive [2]. 
In reviewing the major advances in the chemotherapy of cancer, 
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tyrosinase, showed significant cytotoxicity that is selective to 
melanocytes and melanoma cells. 
Most previous attempts to impair the melanin pathway as a 
therapeutic strategy have been of limited success because they 
have been directed to catecholic compounds that are unstable 
and insufficient in lethality at physiologically tolerable doses. 
By contrast, our approach relies on phenolic compounds, 
PTEs and PTEAs, which are more stable than catechols and 
become toxic only after oxidation by tyrosinase. We found 
PTEA as the most promising agent for the future develop­
ment of chemotherapeutic agents. The possible biologic, 
chemical, and pharmacologic reactions of these synthetic 
compounds within the melanoma cells are studied and dis­
cussed.] Invest DermatoI100:231S-238S, 1993 
it is immediately apparent that the most remarkable successes have 
occurred when the biologic uniqueness of a given tumor was ex­
ploited. The biologic uniqueness of the melanoma cell resides in 
this tendency to retain the biochemical apparatus for the conversion 
of tyrosine to melanin in the highly specialized organelle, the me­
lanosome [3]. This differentiated morphologic and biochemical 
property is unique to the melanocyte and its malignant counterpart, 
and the activity of this pathway is enhanced in most melanoma cells. 
It can also be highly exaggerated, even in amelanotic melanoma, by 
melanocyte stimulating hormone (MSH) (Fig 1). Our previous 
study, using White Leghorn chicken as an animal model of human 
melanoleucoderma, indicated that melanin/melanosome per se, if 
overproduced, is toxic to melanocytes and may even kill them, thus 
providing a rationale for utilizing melanin precursors and metabo­
lites for selective degradation of melanoma cells [4]. 
This report describes, first, the background of the utilization of 
melanin precursors as potential chemotherapeutic agents for mela­
noma by introducing several natural melanin precursors/metabo­
lites, i.e., tyrosine, dopa, dopaquinone, dihydroxyindole, and cys­
teinyldopa, as well as phenol and catechol, which are well-known 
depigmenting agents. We will then summarize our recent ap­
proaches to experimental melanoma chemotherapy, which are 
based on the exploitation of metabolic pathways of melanin syn­
thesis. 
METABOLISM OF MELANIN PRECURSORS AND 
THEIR SELECTIVE MELANOCYTOTOXICITY 
The metabolites of melanin pigmentation that may be useful for 
development of cytotoxic agents can be grouped into two major 
categories: a) enzymic oxidation of tyrosine (monohydroxy)/dopa 
(dihydroxy) and b) auto-oxidation of 5,6-dihydroxyindole (eume-
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Figure 1. Metabolic pathway of melanin synthesis from conversion of tyrosine to dopa and then to dopaquinone in the presence of tyrosinase. 
Eumelanin, brown-black pigment, is synthesized through the oxidation of dihydroxyindole (DHI) with an intimate interaction of dopachrome tautomer­
ase and metal ions. Pheomelanin, yellow-red pigment, is formed through the incorporation of cystein or other related sulphydryl compound, glutathione 
(GSH). Structurally, eumelanin is composed mainly of heteropolymer units of 5,6-DHI and 5,6-dihydroxyindole-2-carboxylic acid whereas pheome­
lanin is made of benzothiazine units. Copolymerization of dopa and cysteinyldopa may take place, leading to the production of mixed-type melanin. 
Trichochrome is a derivative of a conjugated benzothiazine dimer. The drawing is modified from the original figure prepared by Professor Prota. 
lanin)/ 5-S-cysteinyldopa (pheomelanin) [5]. In the past, a number 
of approaches have been used to examine derivatives representing 
each of these metabolites as potential models for the design of com­
pounds that will exhibit useful clinical cytotoxicity for melanoma 
cells. 
Tyrosine Tyrosine serves as the starting material for the biosyn­
thesis of melanin. The degree and type of melanin pigmentation of 
melanoma cells can be influenced by changing the concentration of 
tyrosine or cysteine and related sulfhydryl compound in the growth 
medium [6]. Therefore, through an increased melanotic pigmenta­
tion by raising the concentration of tyrosine, one can induce signifi­
cant toxicity to melanin-groducing cells as compared to their non­
pigmented counterparts [7]. A major difficulty in the application of 
this approach for melanoma chemotherapy is the fact that tyrosine is 
an amino acid used extensively in general cellular protein synthesis. 
In addition, rapidly growing pigmented cells incorporate only 
about 5% of the tyrosine used in general cellular protein synthe­
sis [8]. 
Dopa/Dopamine Although dopa is an amino acid, it is not nor­
mally found in cellular proteins. Exogenous dopa, unlike tyrosine, 
has been shown to be selectively incorporated into melanoma cells 
[9]. Dopa and related catecholic compounds have been shown to 
possess antimelanoma effects in many in vitro and some in vivo sys­
tems [10]. Dopamine, a major metabolite of dopa, has also been 
shown to be a highly potent inhibitor of murine melanoma cell 
proliferation, both in vivo and in vitro. Dopamine has been infused 
into advanced-staged melanoma patients with some reduction in 
the labeling index of tumor cells [11]. The major limitations of dopa 
derivatives appear to be a) instability, b) insufficient lethality of dopa 
toward neoplastic cells in vivo, and c) low physiologically tolerable 
dosages of 6-hydroxydopa and other catechols due to general cyto­
toxicity. A new class of compounds, the dopa phosphates, has been 
reported recently. These compounds, in which either the 3- or 
4-position of hydroxyl groups of dopa are monoesterified with 
phosphate, are stable [12] and, at high concentrations, appear to be 
cytotoxic toward murine melanoma cells in vitro. However, no data 
are available as yet regarding their in vivo antimelanoma effect. 
Dihydroxyindole/Cysteinyldopa Dihydroxyindole is a pre­
cursor of eumelanin produced from dopaquinone by non-enzymic 
reaction. It has been shown to be cytotoxic to melanoma cells in vitro 
[13]. This compound is an extremely reactive neutrophile and elec­
trophile, which limits its use as an antitumor agent. 5-S-cysteinyl­
dopa is also a precursor of pheomelanin, and has also been shown to 
possess an in vitro anti-melanoma effect, which was better than that 
of dopa and was also active against L1210 leukemia [14]. Again, no 
in vivo data were provided. 
Catechols As early as 1974, we studied by electron microscopy 
the subcellular processes occurring during/after topical application 
of hydro quinone to black skin, and clarified the possible mechanism 
of melanocytotoxicity by catecholic compounds [15]. These com­
pounds release quinone derivatives, which selectively affect the mel­
anogenesis and eventually cause melanocyte death. In addition, by 
examining the in vitro incorporation of leucine in a cell-free protein 
inhibition system, one type of catechol, 4-isopropylcatechol, dra­
matically inhibited this process in melanoma cells that contained a 
high level of tyrosinase. The enhanced inhibition was 'also found, 
however, in the cell-free liver system when tyrosinase was added 
(from 0 to 80% inhibition). Aerobic oxidative products of catechol 
were not responsible for this inhibition, indicating that the tyrosin­
ase-dependent cytotoxicity was probably mediated by some inter­
mediate that occurs in an early stage of enzymic oxidation [16]. 
Phenols In the studies of Vogel and colleagues [17,18], a stable 
phenol [gamma-L-glutaminyl-4-hydroxybenzene (GHB)] was 
shown to prolong survival of C57BL mice inoculated with mela­
noma cells and to inhibit the growth of melanoma cells in vivo. 
However, GHB was shown to be a poor substrate of mammalian 
tyrosinase, and hydrolyzed in animals by gamma glutaminyl trans­
peptidase to release p-aminophenol as a product, which is responsi-
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ble for melanocytotoxicity [19]. Thus, GHB itself is not appropriate 
for a rational chemotherapy. 
Recently three new catecholic analogues of GHB have been syn­
thesized as potential antimelanoma drugs. Compounds 1 and 2 
(NSC 337779 and 337780) were found to be oxidized by tyrosinase 
to quinones. Cytotoxic activity was blocked by a tyrosinase inhibi­
tor. These two compounds exhibited greater potency and selectivity 
against melanoma than did the natural product, L dopa-methyl 
ether [20]. Again the in vivo antimelanoma effects of these com­
pounds need to be clarified. Riley and his associates [21] indicated 
that 4-hydroxyanisole is a potent depigmenting agent and has some 
in vivo and in vitro antimelanoma effect in animals and humans. A 
number of rl:cent studies, however, indicated that 4-hydroxyanisole 
does not have any selective cytotoxicity to pigment cells [22]. 
DEVELOPMENT OF TYROSINE HOMOLOGUE, 
CYSTEINYLPHENOL (CP), AND ITS AMINE 
DERIVATIVE, CYSTEAMINYLPHENOL (CAP), AND 
THEIR BIOLOGIC AND PHARMACOLOGIC EFFECTS 
Synthesis ofCP and CAP, and Their Enzymic Kinetics With 
Tyrosinase We have recently synthesized a sulphur homologue 
of tyrosine, cysteinylphenol (CP) and its amine derivative cystea­
minylphenol (CAP), and related compounds [23] (Fig 2). Phenols 
and catechols are combined with sulphur using either cysteine or 
cysteamine to synthesize these phenolic thioethers (PTEs) or their 
amines, phenolic thioether amines (PTEAs), respectively (Table I). 
Sulphur was added, a) because it may increase the uptake of the 
compound into the cells by virtue of lipophilicity, and b) because the 
conjugation of sulphur may make the compound a better substrate 
for tyrosinase. These synthetic compounds include 4-S-cysteinyl­
phenol (CP), 2-S-CP, 4-S-cysteaminylphenol (CAP), 4-S-cystein­
ylcatechol (Ce), 2-S-CC, 2-cysteinylhydroquinone (CHQ), 2-S­
cysteinylresorcinol (CR) , and 2-S-cysteinyldopa (CD). Only 
4-S-CP, 4-S-CAP, and 4-S-CC were found to be tyrosinase sub­
strates but 2-S-isomers were not (Table I). 
1 .. Vivo Melanocytoxicity of CP and CAP in Black/White 
Mice In our initial screening, we tested the in vivo depigmenting 
potency of seven compounds, i.e., 4-S-(2-S)-CP, 4-S-(2-S)-CAP, 
4-S-CC, 2-S-CHQ, and 2-S-CR using C57 black mice. After a 
single intraperitoneal injection of compounds (200 -400 mg/kg of 
body weight), 4-S-CP and 4-S-CAP showed the depigmentation of 
newly growing black hair. Depigmentation was most prominent in 
black mice treated with 4-S-CAP (close to 80%) and then with 
4-S-CP. Catecholic compounds were easily oxidized by air and not 
practical for in vivo study (Table I). None of the depigmentation was 
observed by 2-S-CP and 2-S-CAP, which were not tyrosinase sub­
strates (Table I). Under electron microscopy, degenerating changes 
were seen as early as 2 h after an intraperitoneal administration, 
showing vacuolation of the entire cytoplasm and later, at 48 h, the 
lysis of the whole cell. In contrast, the non-melanin-forming cells, 
e.g., keratinocytes, fibroblasts, and albino melanocytes, did not 
show any degenerative changes [24]. 
1 .. "i"o and 1 .. Vitro Selective Accumulation of CP and CAP 
into Melanoma-Bearing Mice and Melanoma Cells To fur­
ther characterize the selective melanocytotoxicity of melanin pre­
cursors, 4-S-CP and 4-S-CAP were radio labeled with 3H and 14C, 
respectively [25,26], and their incorporation into melanoma tissues 
were evaluated in B16 melanoma-bearing mice. Silver grains of 
4-S-CP were selectively accumulated in melanoma cells, whereas 
they were not seen in necrotic tissues [27]. 14C-4-S-CAP showed a 
biodistribution similar to that of 4-S-CP. It was, however, also 
incorporated into the eye [28]. 
We further tested this selective incorporation of PTEA in mela­
noma cells in an in vitro system. Human melanoma cells (SK-MEL 
23) showed an increased incorporation of 14C-4-S-CAP up to 
5 min, approximately threefold incorporation as compared to that 
of HeLa cells and fibroblasts. Once incorporated into melanoma 
cells, 4-S-CAP was not released into fresh culture medium, indicat­
ing the selective accumulation of 4-S-CAP in the cell. Besides the 
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selective transport system through membrane recognition of either 
cell surface or melanosome-parricle surface, there may be a number 
of possibilities to account for this selective accumulation of CAP in 
melanoma cells, and all these are related to the intramelanocytic 
metabolisms, e.g., a) enzymic reactions of tyrosinase-related pro­
teins such as dopachrome tautomerase or b-Iocus protein (HMSA-5) 
[29,30] or b) a specific binding property of PTE A to melanin metab­
olites in a way similar to that of chloroquine and quinone derivatives 
[31]. 
1 .. Vivo Antimelanoma Effect of CP and CAP, and Increased 
Survival The in vivo antimelanoma effects of CP, CAP, and re­
lated compounds were evaluated by a) direct growth inhibition of 
murine melanoma and b) the increased life-span (ILS) of B16 mela­
noma-bearing mice (Table I) [23]. 4-S-CAP showed the highest 
antimelanoma effect on the growth inhibition (45-53%). 4-S-CP 
also showed some growth inhibition (33%), which was still better 
than that of DTIC (NSC 45388; 23%), a drug known to be most 
consistently effective for human melanoma. Importantly, 4-S-CAP 
possessed a significant antimelanoma effect in ILS (49%). Similar to 
depigmenting potency, the in vivo antimelanoma effect was seen 
only with 4-S-CP and 4-S-CAP, tyrosinase substrates, but not with 
their 2-S-isomers, which were not tyrosinase substrates (Table I). 
4-S-CP and 4-S-CAP require a catalytic amount of dopa for optimal 
mammalian tyrosinase activity. The majority of L-dopa, when ad­
ministered intravenously, was decarboxylated (ap\?roximately 64%) 
and metabolized into catecholamine pathway [32]. To enhance the 
potential anti-melanoma effect and to inhibit the decarboxylation 
of these two synthetic compounds, L-dopa and antidecarboxylase 
(carbidopa) were given simultaneously. Whereas groups of 4-S-CP 
plus L-dopa plus carbidopa showed a minimal increase in antime­
lanoma effect, the group treated with 4-S-CAP plus L-dopa plus 
carbidopa revealed an increased inhibition in in vivo melanoma 
growth (64%) as compared to that of 4-S-CAP alone (49%) [33]. 
1 .. Vitro Transport Mechanism of CP Into Melanoma Cells 
How melanin precursors/tyrosinase substrates are transported into 
pigment cells is still unknown. The transport system of 4-S-CP was 
studied in comparison to that of tyrosine for this purpose. Firstly, we 
determined which one, or combination of, amino acid transport 
systems, e.g., systems L and T (which transport neutral amino acid 
with branched or aromatic side chains), and systems A and ASC 
(which transport neutral amino acid with smaller side chains), 
would be involved in tyrosine transport into melanoma cells. Our 
result of Km and Vmax for the Na+-independent transport system 
and competitive inhibition studies indicated that system L is in­
volved in tyrosine transport. This one transport system supplies all 
the tyrosine required for both cell growth and melanin synthesis. 
Secondly, studies of sequential competitive inhibition tests between 
tyrosine and 4-S-CP were carried out, and 4-S-CP was found to 
share the same system L transport for the incorporation into mela­
noma cells [34]. 
1 .. Vitro Inhibition of Protein Synthesis, and Tyrosinase-Me­
diated Conjugation with SH-Enzymes We then have clari­
fied to what extent and how protein synthesis is inhibited by PTEs 
and PTEAs. Firstly, we studied the inhibitory effects of CP, CAP, 
and their analogues on protein synthesis. The incorporation of leu­
cine into protein was inhibited significantly by 4-S-CP (9.3%), 
4-S-CAP (30.5%), and 4-S-CC (35.0%) (Table I). The rates of 
protein synthesis inhibition by natural melanin precursors, e.g., 
tyrosine, dopa, and 5-S-cysteinyldopa, were practically zero or min­
imal, being -6.6%, -3.6%, and 6.9% respectively. Secondly, 
treatment of human melanoma cells with 4-S-CAP for 24 h re­
sulted in a slight increase in the proportion of cells in G2 plus M 
phase of the cell cycle. Simultaneous treatment with Colcemid (1 
mg/ml) blocked the controls in G2 + M, but had little effect on the 
DNA synthesis of the 4-S-CAP-treated cultures, indicating that 
there was no phase-specific arrest of the cell cycle by 4-S-CAP. 
When the tyrosinase activity and the amount of tyrosinase itself was 
measured, 4-S-CAP -treated cells showed a marked decrease of the 
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Figure 2_ Chemical structures and synthetic processes of phenolic thioethers (PTEs) and their amine or amide derivatives, phenolic thioether amines 
(amides) (PTEAS). 
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Table I. Chemical Structure, Protein Synthesis Inhibition, Enzyme Kinetics, and Antimelanoma Effects 
Kinetics with Tyrosinase-
Percent Melanoma Tyrosinase Mediated 
Depigmenting Inhibition of Conjugation In Vivo Percent Melanoma 
Compound Potency! Protein Synthesis Km Vmax with ADH Growth Inhibition 
4-S-CP' + 9.3 ± 1.2 0.021 2.3 3.6% 32.5 
2-S-CP' 9.4±0.5 0.0 Nor 
4-S-CAPh +++ 30.5 ± 1.6 0.031 2.3 17.0% 45.1, 49.0, 53.3 
2-S-CAPh 5.3 ± 7.3 0.0 NO 
4-S-CC' ± 35.0±4.0 Substrate 4.7% 
2-S-CHQ' 
2-S-CR' 
• 4 (2)-S-CP; 4(2)-S-cysteinylphenoI. 
• 4 (2S)S-CAP; 4(2)-S-cysteaminylphenoI. 
, 4-S-CC; 4-S-cysteinylcatecboI. 
4 2-S-CHQ; 2-S-cysteinylhydroquinone . 
• 2-5-CP; 2-5-cysteiny1resorcinoI. 
15.7±5.2 0.0 NO 
3.2±5.6 0.0 NO 0 
f Depigmenting potency was examined after a single intraperitoneal administration of synthetic compounds into C57 black mice (see Fig 3). 
, NO, not determined. 
activity, suggesting the involvement of enzymic reaction of tyro­
sinase in 4-S-CAP-mediated toxicity [35]. Thirdly, the in vitro 
reaction of CP and CAP with intracellular thiol-dependent en­
zyme, e.g., DNA polymerase a, was studied. As the model of a 
thiol-dependent enzyme, we employed alcohol dehydrogenase 
(AD H). In the presence of tyrosinase, we found that both 4-S-CP 
and 4-S-CAP reacted with cysteine residues in ADH, and that 4-S­
CAP possessed a higher ability for binding with ADH, as much as 
five times that of 4-S-CP, explaining partly a much higher melano­
cytotoxicity potency, protein synthesis inhibition, and antimelan­
oma effect of 4-S-CAP than 4-S-CP (Table I) [36]. 
Development of New Analogues of 4-S-CAP, and their Tyr­
osinase and Non-Tyrosinase-Mediated Cytotoxicity One 
of the difficulties in utilizing 4-S-CAP as an in vivo antimelanoma 
agents was that it had a limited solubility and a low LDso value. 
Furthermore, in an attempt to develop antihypertensive agents, 
Padgette et al [37] prepared 4-S-CAP and found this compound to be 
a good substrate for plasma monoamine oxidase. Kawase et al [38] 
previously reported that various 3-substituted propylamines exerted 
cytotoxicity through corresponding aldehydes produced by enzy­
matic oxidation and deamination. Indeed, we found that the low 
LDso of 4-S-CAP may be attributable to this monoamine-oxidase 
interaction. To overcome this difficulty a new derivative of 4-S­
CAP, N-Acetyl(Ac)-4-S-CAP, was prepared and tested in vivo cyto­
toxicity. We found that N-Ac-4-S-CAP possesses a high LDso 
value. It was a substrate of mammalian tyrosinase, but not of mono­
amine oxidase [39], and its LDso was 1,400 mg/kg of body weight. 
In addition, five other homologues ofN-Ac-4-S-CAP were synthe­
sized; a-methyl-4-S(2-S)CAP, 4-S(2-S)-homo-CAP, and N,N'-di­
methyl-4-S-CAP. Firstly, their in vitro melanocytoxicity was tested 
[40]. 4-S-CAP and 4-S-homo-CAP exhibited a marked melanocy­
totoxicity to cultured human melanoma cells with effects much 
greater (40 times) than those of a-methyl-4-S-CAP and N,N'-di­
methyl-4-S-CAP. The cytotoxicity of the two former amines was 
completely prevented by semicarbazine, a monoamine oxidase in­
hibitor. Alpha-methyl-4-S-CAP was, however, found to exert 
higher cytotoxicity to cultured cells with higher tyrosinase activity 
and melanin content. These results suggest that the in vitro cytotox­
icity of 4-S-CAP and 4-S-homo-CAP is mediated through conver­
sion to aldehydes, whereas that of a-methyl-4-S-CAP is solely de­
pendent on tyrosinase activity. We expect that N-Ac-4-S-CAP will 
take the same tyrosinase-dependent melanocytotoxicity (Table II). 
In Vivo Melanocytotoxicity by N-Ac-4-S-CAP and Related 
Compounds We then tested the melanocytotoxicity of these six 
new compounds by in vivo depigmenting potency using murine 
black hair follicles. Follicular melanocytes were examined to assess 
the degree of melanocytotoxicity; N-Ac-4-S-CAP produced the 
highest degree of melanocytotoxicity (98%), both given intraperito-
neally or subcutaneously (Fig 3). a-methyl-4-S-CAP and 4-S-CAP 
were almost equally effective in intraperitoneal administration, 
their melanocytotoxicity potency being 89% and 87%, respectively. 
A similar melanocytotoxicity potency was observed in dark skin 
treated topically with N-Ac-4-S-CAP [41]. Interestingly, 4-S­
homo-CAP showed a minimum degree of melanocytotoxicity po­
tency intraperitoneally (12%), whereas a much higher melanocyto­
toxicity was noted subcutaneously (64%) as compared to that of 
a-methyl-4-S-CAP (58%) and 4-S-CAP (47%) subcutaneously 
(Table II) [42]. 
In Vivo Antimelanoma EfFect by N-Ac-4-S-CAP Extending 
the above screening, the in vivo antimelanoma effect is tested in mice 
that are inoculated with murine and human melanoma cells. We 
firstly tested, after intraperitoneal injections of 4-S-CAP or N-Ac-
4-S-CAP, the inhibition of lung colony formation by B16 FlO 
melanoma cells in C57 black mice. 4-S-CAP and N-Ac-4-S-CAP 
were almost equally effective, reducing the lung colonies to 32% 
and 25% of mean control respectively [42]. Secondly, the same in 
vivo antimelanoma effect was tested in mice with subcutaneously 
inoculated B 16 melanoma tissues. A dose-dependent antimelanoma 
effect was observed in N-Ac-4-S-CAP given from 200 mg/kg to 
1200 mg/kg, showing 32% and 71 % growth inhibition, respec­
tively [33]. Thirdly, in vivo antimelanoma effect ofN-Ac-4-S-CAP 
Figure 3. Development of white amelanotic hair in C57 black mice after 
a single intraperitoneal injection of N-Ac-4-S-CAP (400 mg/kg). To syn­
chronize the hair cycle, black hair was epilated and then N-Ac-4-S-CAP 
was given at day 5. 
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Table n. Enzyme Kinetics of N-Ac-4-S-CAP and Other New Derivatives and Their Melanocytotoxicity In Vivo" 
Tyrosinase 
Monoamine 
Oxidase 
Compounds 
Control 
N-Ac-4-S-CAP' 
a-Me-4-S-CAP' 
4-S-CAPd 
4-S-Homo-CAP' 
N,N' -Di-Me-4-S-CAPf 
SR 
SCH2CH2NHCOCH3 
SCH2CH1CHNH2 
SCH2CH2NH2 
SCH2CH2NH2 
SCH2CH2N(CH3h 
• 
After a single intraperitoneal injection (300 mg/kg). 
• N-Ac-4-S-CAP: N-Acetyl-4-S-cysteaminylphenol. 
, a-Me-4-S-CAP: a-methyl-4-S-cysteaminylphenol. 
J 4-S-CAP: 4-S-cysteaminylphenol. 
• 4-S-Homo-CAP: 4-S-Homocysteaminylphenyl. 
J N,N' -Di-Me-4-S-CAP: N,N'-dimethyl-4-S-cysteaminylphenol. 
I<m 
1000 
114 
117 
133 
108 
was tested in human tumor xenografts in nude mice. We found that 
200 mg/kg of 4-S-CAP and 400 mg/kg ofN-Ac-4-S-CAP induced 
significant inhibition of tumor growth by 17 d when injected intra­
peritoneally at 3-d intervals. No effect on the ovarian tumor cell line 
JAM was observed [35]. 
D ISCUSSION AND CONCLUSION 
Melanin biosynthesis in mammals involves the step-wise conver­
sion of tyrosine or dopa into a number of compounds that polymer­
ize to form the end product. melanin. The initial reaction in this 
pathway is mediated through tyrosinase that is, in general, highly 
elevated in melanoma. Figure 4 outlines four major biochemical, 
chemical, and physical reactions (steps) that may be anticipated to 
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In Vivo Melanocytotoxicity 
0.0% 
97.6% 
88.9% 
86.9% 
12.1 % 
7.3% 
occur during metabolism of PTEs and PTEAs within melanoma 
cells, with a comparison to those metabolic pathways due to natural 
melanin metabolites, tyrosine, dopa, dopaquinone, and melanin. 
These major reactions include a) transport PTEs and PTEAs in 
melanoma cells, b) oxidation and formation of semiquinone radicals 
by tyrosinase, c) formation of pseudomelanin and detoxication by 
glutathione (GSH), and d) selective accumulation through recep­
tors or binding proteins or tyrosinase-related proteins (Fig 4). 
Monoaminergic cells, especially monoaminergic neurons, pos­
sess/share many biologic and biochemical properties in common 
with melanocytes. Both cell types are dendritic, derive from the 
neural crest, produce specific granules (chromaffin granules or mela­
nosomes), and convert tyrosine to produce pigments (catechol­
amines or melanin) in the presence of enzyme (tyrosine hydroxylase 
or tyrosinase). Monoaminergic cells possess two transport systems, 
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Figure 4. Major four steps occurring during biochemical, chemical, and physical reactions in the metabolic processes of phenolic thioethers (PTEs) or 
phenolic thioether amines (amides) (PTEAs). These four steps of reactions are compared with those reactions in the metabolic pathway of melanin 
synthesis from tyrosine and dopa in the presence of tyrosinase. These reactions would be intimately interacted to cause the selective melanocytotoxicity 
of PTEs and PTEAs. 
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Pigure S. Production of secondary radicals from cyclizing and non-cy­
clizing quinones and formation of "pseudomelanin" through oxidation of 
phenolic thioether amine in the presence of tyrosinase. 
one located in the plasma membrane and the other in vesicles. The 
vesicular transport has been studied in chromaffin granules, bur 
monoamines taken up into other vesicles probably use a similar 
mechanism. This biogenic amine transporter is responsible for ac­
cumulation of serotonin, dopamine, norepinephrine, and epineph­
rine in the vesicles. The energy required for the amine accumulation 
comes from ATP-driven H+ pump in the vesicle membrane. The 
ionic form of the amine that binds to the transporter is not known, 
but some evidence suggests that the amine is transported in its un­
charged form. The chromaffin granule transporter has low specific­
ity; it translocates with similar efficiency not only dopamine, norepi­
nephrine, and epinephrine, but also monoamines that are not 
present in the adrenal medulla, such as serotonin and tyramine. 
Monoaminergic cells also possess a second class of monoamine up­
take systems located on the plasma membrane. These systems are 
secondary active transporters but differ from the vesicular system. 
Our synthetic PTEAs may take uptake processes similar to those 
of the above amine transport. However, melanoma cells may also 
have specific binding proteins [43]. The latter possibility of selective 
accumulation and incorporation of PTEAs to melanoma cells would 
be direcdy or indirecdy related to some important intracellular en­
dogenous metabolic pathway [44,45,46]. Our PTEAs selectively 
disintegrated in vivo the melanocytes that were engaged in active 
melanin biosynthesis, but not albino melanocytes, in which there 
was no melanin biosynthesis and active tyrosinase. Melanin biosyn­
thesis involves several steps of reduction and oxidation initialed by 
tyrosinase. As can be seen in Figs 4 and 5, we expect that the same 
reaction would happen to our PTEAs, forming melanin-like pig­
ments. We therefore suspect that radicals are involved in the PTEA 
melanocytotoxicity. The cyclizing quinones from PTEAs can give 
rise to two structural isomers and, accordingly, two different types 
of secondary radicals (I and II) can be formed as specified in Fig 5. 
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The intracellular level of glutathione may also control the toxic 
effect of these radicals [47,48]. 
As a possible explanation of the cytotoxicity of substitute phenols, 
e.g., 4-hydroxyanisole, Riley [21] proposed that tyrosinase-cata­
lyzed oxidation gives rise to ortho-quinones that exhibit a relatively 
high degree of reactivity. In studies of catechols, e.g., L-dopa, and 
gamma-L-glutaminyl-4-hydroxybenzene, Graham et al [49] have 
postulated that catechols are oxidized by tyrosinase to o-quinone 
forms that react with sulphydryl reagents, thus inhibiting the activ­
ity of thiol-dependent cellular enzymes such as DNA polymerase a. 
Similarly, CP and CAP can be oxidized by tyrosinase to catecholic 
forms (cysteinylcatechol and cysteaminylcatechol) and then to the 
corresponding quinone forms that may conjugate with sulphydryl 
enzyme in cells. We found that both 4-S-CP and 4-S-CAP conju­
gate with cysteine residues in sulphydryl enzyme. The sulphydryl 
enzyme can therefore be another source of PTEA-binding protein 
within melanoma cells. 
In conclusion, we have recendy synthesized 23 compounds of 
sulphur homologue of melanin precursors and related analogues to 
establish a rational chemotherapeutic agent for melanoma based 
upon melanin biosynthesis. 4-S-CP and 4-S-CAP are tyrosinase 
substrates and found to be potent melanocytotoxic and anti-melan­
oma agents, 4-S-CAP being much better than 4-S-CP. 4-S-CAP, 
however, has some inherent difficulty in practical use. New com­
pounds, N-Ac- and a-methyl-4-S-CAP, were developed. Both 
showed a marked in vivo melanocytotoxicity (78-99%). Impor­
tandy, N-Ac-4-S-CAP, which was found to be a good tyrosinase 
substrate, showed 75% of in vivo growth inhibition of melanoma 
cells grown in mice. Melanin synthesis pathway is highly elevated 
in malignant melanoma. This pathway, however, does not play any 
essential role in the host. Therefore, the potential agent need not 
discriminate between normal and malignant cells, but rather melan­
ocytic and non-melanocytic cells. 
This study was fUMed by grants from the National Cancer Institute of Canada, 
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